{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:30:04Z","timestamp":1783625404247,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:13:20Z","timestamp":1766128400000},"page":"131-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo De","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Ganguli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.11.015_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2025.11.015_b0010","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cncr.23293","article-title":"A nomogram predicting long-term biochemical recurrence after radical prostatectomy","volume":"112","author":"Suardi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0015","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above","volume":"95","author":"Kupelian","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2025.11.015_b0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0030","unstructured":"Astellas Pharma US Inc. Full prescribing information: XTANDI\u00ae (enzalutamide) for oral use. https:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-WPI.pdf."},{"key":"10.1016\/j.euf.2025.11.015_b0035","unstructured":"European Medicines Agency. Xtandi: European public assessment report \u2013 product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi."},{"key":"10.1016\/j.euf.2025.11.015_b0040","unstructured":"Health Canada. Regulatory decision summary for Xtandi\u00ae. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS1714051494769."},{"key":"10.1016\/j.euf.2025.11.015_b0045","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.11.015_b0050","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euf.2025.11.015_b0055","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 1.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"10.1016\/j.euf.2025.11.015_b0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0065","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532)","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5454727","article-title":"Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2025.01.001","article-title":"Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Tsuboi","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.11.015_b0085","doi-asserted-by":"crossref","unstructured":"Fazekas T, Miszczyk M, Giesen A, et al. Androgen receptor pathway inhibitor monotherapy in prostate cancer: safety, oncologic outcomes, and quality of life\u2014a systematic review and meta-analysis. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.05.006.","DOI":"10.1016\/j.euf.2025.05.006"},{"key":"10.1016\/j.euf.2025.11.015_b0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/abs-20-124","volume":"5","author":"Sharp","year":"2021","journal-title":"Gynecomastia. Ann Breast Surg"},{"key":"10.1016\/j.euf.2025.11.015_b0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1677\/erc.0.0060315","article-title":"Aromatase and gynecomastia","volume":"6","author":"Braunstein","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0100","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0105","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-018-0738-5","article-title":"Patterns of bicalutamide use in prostate cancer treatment: a U.S. real-world analysis using the SEER-Medicare database","volume":"35","author":"Beebe-Dimmer","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.euf.2025.11.015_b0110","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.11.015_b0115","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.2217\/fon-2019-0563","article-title":"Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan","volume":"15","author":"Shah","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.euf.2025.11.015_b0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1464-410X.2006.06275.x","article-title":"Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration","volume":"98","author":"Tyrrell","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.11.015_b0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.11.015_b0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.pcan.4500799","article-title":"Bicalutamide (\u2018Casodex\u2019) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme","volume":"8","author":"Wirth","year":"2005","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.11.015_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136094","article-title":"Gynecomastia in patients with prostate cancer: a systematic review","volume":"10","author":"Fagerlund","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2025.11.015_b0145","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.3747\/co.19.993","article-title":"Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis","volume":"19","author":"Tunio","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0150","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1016\/j.ijrobp.2012.01.036","article-title":"Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?","volume":"83","author":"Viani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.11.015_b0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.euf.2025.11.015_b0160","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.juro.2017.08.103","article-title":"Long-term antitumor activity and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 3-year open label followup results","volume":"199","author":"Tombal","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2025.02.006","article-title":"Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: a post hoc analysis of patient-reported outcomes in the EMBARK study","volume":"87","author":"Freedland","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0280","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.juro.2010.03.137","article-title":"Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and\/or breast pain?","volume":"184","author":"Ozen","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0195","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.11.015_b0185","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdon\u00e0","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0180","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/01.ju.0000181824.28382.5c","article-title":"Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy","volume":"174","author":"Di Lorenzo","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clgc.2012.03.002","article-title":"A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia","volume":"10","author":"Serretta","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","article-title":"An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients","volume":"57","author":"Bedognetti","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2007.01.031","article-title":"Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study","volume":"52","author":"Fradet","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.pcan.4500782","article-title":"Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole","volume":"8","author":"Saltzstein","year":"2005","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.11.015_b0215","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2005.12.013","article-title":"Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0285","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1999.17.7.2027","article-title":"Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study","volume":"17","author":"Boccardo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.015_b0190","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.PRS.0000042146.40379.25","article-title":"Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction","volume":"111","author":"Rohrich","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.euf.2025.11.015_b0225","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euf.2025.11.015_b0230","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.11.015_b0235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","article-title":"Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"28","author":"Matsukawa","year":"2025","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.11.015_b0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41416-018-0369-2","article-title":"Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis","volume":"120","author":"Eggemann","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2025.11.015_b0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-009-0379-0","article-title":"Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database","volume":"119","author":"Brinton","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.euf.2025.11.015_b0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijrobp.2018.01.096","article-title":"Does prophylactic radiation therapy to avoid gynecomastia in patients with prostate cancer increase the risk of breast cancer?","volume":"101","author":"Aksness\u00e6ther","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.11.015_b0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.11.015_b0260","doi-asserted-by":"crossref","first-page":"E467","DOI":"10.1097\/NCC.0000000000000918","article-title":"Development of the Prostate Cancer Treatment Decision framework: a context-specific expansion of the risk-as-feelings hypothesis","volume":"44","author":"Owens","year":"2021","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.euf.2025.11.015_b0265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/cer.14.41","article-title":"Development, characteristics and validity of the EORTC QLQ-PR25 and the FACT-P for assessment of quality of life in prostate cancer patients","volume":"3","author":"Chu","year":"2014","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.euf.2025.11.015_b0270","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8364824","article-title":"Clinical and etiological aspects of gynecomastia in adult males: a multicenter study","volume":"2018","author":"Costanzo","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.euf.2025.11.015_b0275","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/SAP.0000000000000940","article-title":"Management of gynecomastia in patients with different body types: considerations on 312 consecutive treated cases","volume":"78","author":"Innocenti","year":"2017","journal-title":"Ann Plast Surg"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:29:14Z","timestamp":1773937754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925003475"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.015","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}